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Retrotransposition of human LINE-1 (L1) element, a major representative non-LTR retrotransposon in the human genome, is known
to be a source of insertional mutagenesis. However, nothing is known about eﬀects of L1 retrotransposition on cell growth and
diﬀerentiation. To investigate the potential for such biological eﬀects and the impact that human L1 retrotransposition has upon
cancer cell growth, we examined a panel of human L1 transformed cell lines following a complete retrotransposition process. The
results demonstrated that transposition of L1 leads to the activation of the p53-mediated apoptotic pathway in human cancer cells
that possess a wild-type p53. In addition, we found that inactivation of p53 in cells, where L1 was undergoing retrotransposition,
inhibited the induction of apoptosis. This suggests an association between active retrotransposition and a competent p53 response in
which induction of apoptosis is a major outcome. These data are consistent with a model in which human retrotranspositionis sensed
by the cell as a “genetic damaging event” and that massive retrotransposition triggers signaling pathways resulting in apoptosis.
INTRODUCTION
Retrotransposons are mobile retroelements that uti-
lize reverse transcriptase and RNA intermediate to relo-
cate to new locations within the cellular genome. Retro-
transposons are subdivided into two subclasses: LTR-
(long terminal repeats) and non-LTR-retrotransposons
[1, 2]. Non-LTR-retrotransposons are typiﬁed by the
LINE-1 (long interspersed nuclear element 1), or L1, in
mammals [3, 4]. L1 is one of the repetitive sequences in
thegenome,with500000copiescomprisingabout17%of
the genome [5, 6, 7]. Most human L1s (> 99.8%) are un-
able to transpose as a result of 5  truncations, rearrange-
ments, or nonsense mutations [8, 9]. However, evidence
exists that L1 transposition continues to occur.
Several examples of de novo transposition events have
been identiﬁed largely as the result of germline and so-
matic mutations caused by the insertion of new L1 ele-
mentsintofunctionalgenes[10,11,12,13,14,15,16,17].
Constitutive methylation of CpG sites in an L1 promoter
is considered to be one of the major mechanisms for re-
pression of retrotransposition [18, 19, 20]. In these cases,
the CpG sites in an L1 promoter are normally heavily
methylated [21] and demethylation of core CpG sites in
the promoter leads to increased levels of L1 transcription
[18]. Interestingly, demethylation and subsequent activa-
tion of an L1 promoter have been observed in bladder
cancer cells [22], suggesting that release of the methy-
lation constraints and activation of L1 may be a com-
mon cancer-associated event. Indeed, DNA methylation
is considered to be an important mechanism for silenc-
ing retroelements in the mammalian genome, and it has
been demonstrated that loss of genomic methylation ac-
t i v a t e sL 1e l e m e n t sa n dc a u s e sp53-dependent apoptosis
[23]. Thus, there seem to be selective pressure for silenc-
ing of L1 in “normal” cells and contrary activation of L1
in cancer cells.
In this paper we show that L1 elements capable
of high-frequency retrotransposition in cultured human
cells have a diﬀerential impact upon cell growth de-
pending on the cells p53 status. Human cancer cells that
contained a functional p53 underwent apoptosis follow-
ing L1 retrotransposition, while human cancer cells mu-
tant for p53 did not. These results imply that increased186 Abdelali Haoudi et al 2004:4 (2004)
retrotransposition is recognized as DNA damage and
demonstrate that active retrotransposition by L1 induces
p53-dependent cell killing.
MATERIAL AND METHODS
Cellculture,antibodies,andplasmids
HCT-116, SW480, and DLD-1 were maintained
in Dulbecco’s modiﬁed Eagle’s medium (DMEM)/F-12
(Gibco-BRL, Calif) with 10% fetal bovine serum (FBS),
1% L-Glutamine, and 1% penicillin-streptomycin, in
the presence of 5% CO2/95% air at 37◦C. HT1080wt,
HT1080mut, and MCF-7 were maintained in Iscove’s
modiﬁed Dulbecco’s medium (Gibco-BRL) with 10%
FBS, 1% L-Glutamine, and 1% penicillin-streptomycin.
Normal human ﬁbroblasts (NHF) were maintained in
Dulbecco’s modiﬁed Eagle’s medium (DMEM)/H-21
with 10% FBS, 1% L-Glutamine, and 1% penicillin-
streptomycin.
The antibodies anti-p53, anti-Bcl2, anti-Bax, and
anti-HRP-conjugatedsecondaryantibodywerepurchased
fromSantaCruzBiotechnology,Calif.Anti-α-tubulinwas
purchased from Sigma (Saint Louis, Mo). The plasmid
pJM101 containing human L1 tagged with an antisense
NEO cassette was obtained from John V. Moran (Uni-
versity of Michigan Medical School, Mich). The control
plasmid, pBRV1 containing only NEO gene under SV40
promoter, was a gift from Vladimir Larionov (NCI, NIH)
and has been previously described [24]. The plasmids
p1321 (E6), normal E6/E7 and a control E6/E7 deﬁcient
plasmid, p1318 (∆E6) were obtained from Peter M. How-
ley (Harvard Medical School Mass). The HPV16 E6/E7
containingconstructused,p1321,hasbeendescribedpre-
viously [25]. To construct the plasmid, a SalI/HindIII
fragment containing the E6/E7 ORFs of HPV16 was lig-
ated to the HindIII/SalI site in the p1318 vector, which
contained a human β-actin enhancer/promoter and a β-
actin 3  UTR polyadenylation signal sequence. A control
E6/E7-deﬁcient plasmid p1318 was produced by remov-
ing the SalI/HindIII fragment.
CelltransfectionandL1retrotranspositionassay
5 × 105 cells were seeded in 60mm dishes and
grown to 70% conﬂuence. Transfections were carried
out using lipofectamine (Gibco-BRL). 2µg of plasmid
pJM101DNAand8µLoflipofectaminereagentwereused
for each transfection. pJM101 contains a complete hu-
man L1 and is marked with two selectable genes, hy-
gromycin and neomycin [26]. 16 hours after transfec-
tion the medium was changed, and 3 days later, HygR
cells were selected by growth in the medium containing
250µg/mL hygromycin for 14 days (Figure 1). HygR cells
were trypsinized and plated in growth medium contain-
ing 300–400µg/mL G418. After 14 days the resistant cells
(G418R) were either ﬁxed and stained to score the retro-
transposition frequency or collected for DNA and protein
extractions.
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Figure 1. Retrotransposition rationale. L1 plasmid is tagged
with an antisense copy of the indicator gene NEO, which is dis-
rupted by an intron, (I), in the sense orientation of L1. The
NEO gene is ﬂanked by a heterologous promoter (P2) and a
polyadenylation signal (An). This ensures that G418R cells will
only appear when an L1 transcript (P1: L1 promoter) is spliced
(SD: splicing donor, SA: splicing acceptor), reverse transcribed,
and reintegrated into chromosomal DNA, thus allowing expres-
sion of the uninterrupted NEO gene (NEO active). L1 tagged
constructissubclonedintopCEP4expressionvector,whichcon-
tains hygromycin selectable marker gene.
Retrotranspositionfrequencyandcolony
formingability
Retrotransposition frequency was scored as the num-
ber of G418R colonies per 106 HYGR cells plated. 106
HygR cellswereplatedintriplicateinthepresenceofG418
and maintained for 14 days under this selection. Growing
clones were ﬁxed, stained with Giemsa stain solution, and
counted.
For the colony forming ability, one thousand cells
(103) from HCT-116 and SW480 cell lines, either mock
transfected or transfected with L1 and selected for either
hygromycin or G418 resistance, were plated in triplicate.
Colony forming ability is determined as the number of
colonies generated from 103 plated cells and given as a
percentage.
Polymerasechainreaction
Genomic DNA was extracted using DNAzol reagent
(Molecular Research Center, Inc, Ohio). PCR was carried
out in 50µL reaction volume. Each PCR reaction con-
tained 4mM MgCl2,5 µL1 0Xb u ﬀer, 0.2mM dNTPs,
200ngofeachprimer,10UofTaqpolymerase,and200ng
of DNA template. The reactions were carried out under
the following conditions: 94◦C for 10 minutes, 30 cycles
of 94◦Cf o r1m i n u t e ,6 4 ◦C for 30 seconds, and 72◦Cf o r
30 seconds, then 72◦C for 10 minutes. One ﬁfth of the2004:4 (2004) Human LINE-1 Induces Apoptosis in Cancer Cells 187
reaction volume was loaded and separated on 1% agarose
gels containing ethidium bromide.
Immunoblotting
Cells, either mock-transfected or transfected with
pJM101orpBRV1(ascontrol),werelysedinthefollowing
buﬀer: 120mM NaCl, 25mM Tris, pH 7.5, 1% Triton
x-100, and protease inhibitors cocktail (Complete Mini,
Roche, Germany). The cells were centrifuged and the
proteins collected and quantiﬁed using the Bio-Rad as-
say (Bio-Rad, Calif). The proteins were electrophoresed
through 12% SDS-polyacrylamide gels, and transferred
to nylon membranes (Immobilon-P). The membranes
were ﬁrst incubated in 5% blocking solution (nonfat dry
milk in 1 X PBS) for two hours at room temperature,
then incubated in blocking solution overnight at 4◦Cwi t h
a primary antibody: anti-p53 (1 : 500 dilution), anti-
Bcl2 (1 : 500 dilution), anti-Bax (Santa Cruz Biotechnol-
ogy) (1 : 250 dilution), or anti-α-tubulin (Sigma, Saint
Louis, Mo) (1 : 1000 dilution) as a loading control. The
membranes were washed ﬁrst for 15 minutes and then
4 times for 5 minutes each in PBST (PBS 1 X + 0.1%
Tween 20). The blots were incubated in blocking solu-
tion for 45 minutes at room temperature with the sec-
ondary HRP-conjugated antibody (Santa Cruz Biotech-
nology), and washed in PBST as described above. The de-
tection was performed using the Western Blotting Lumi-
nol Reagent (Santa Cruz Biotechnology).
Apoptosisdetectionassay
Apoptosis was assayed using TiterTACS kit (Trevi-
gen, Md) following the manufacturer’s recommendations
on cells plated and ﬁxed in 96-well plates. Cells were
either mock-transfected or transfected with L1 plasmid
(pJM101) or with NEO plasmid (pBRV1) and selected for
G418 resistance. As a control, cells were treated with nu-
clease allowing complete degradation of DNA. TiterTACS
is a colorimetric assay to quantify apoptosis by detecting
DNA fragmentation in cells.
Inactivationofp53byhumanpapillomavirus
E6/E7genes
HCT116 cells were seeded in 6-well dishes (2 × 105
cells/well) and grown to 70% conﬂuence in DMEM-
complete media. First, cells were transfected with pJM101
and selected for hygromycin resistance as described ear-
lier.After14days,theHygR cellsweretrypsinized,pooled,
andexpandedinDMEM-Hyguntil70%conﬂuence.HygR
cells were then transfected with either no DNA (mock),
1µg of complete E6 (E6), or 1µgo f∆E6 (E6-deleted
form) plasmid DNA and 8µL of lipofectamine reagent.
Threedayslater,thecellswereplacedinDMEM-complete
containing 300–400µg/mL G418 (DMEM-G418). After
10–14 days, the G418R cells were ﬁxed and stained with
0.4% Giemsa solution for visualization and counting. The
number of G418R colonies was scored and the retrotrans-
position frequency was determined.
RESULTS
HumanL1retrotranspositionincancercells
In order to investigate the impact of human L1 trans-
position on cancer cell growth, we ﬁrst established sta-
ble transformants using a retrotransposition assay which
employed a selectable molecular marker in cultured cells
(Figure 1). The assay is based on the excision of an
inverted intron from a neomycin phosphotransferase
(NEO)g e n e[ 26]. Before retrotransposition the intron
prevents NEO expression. During retrotransposition the
intron is spliced out of the RNA intermediate and allows
NEO expression upon reinsertion of the L1. We analyzed
two colorectal cancer cell lines with diﬀerent p53 status:
HCT-116 (p53wt) and SW480 (p53mut) for their ability
to allow L1 retrotransposition by measuring their colony
forming ability before and after transfection with L1 plas-
mid (Figure 2a). Both celllines showed similar survivabil-
ity, and both seem to equally support transfection with
L1 and selection with hygromycin, as demonstrated in the
colonyformationassay.Interestingly,wefoundadramatic
diﬀerence between the two cell lines in the outcome of
G418 selection, which allows for selection of cells harbor-
ing retrotransposition events. Indeed, while we were able
to recover-large number of G418R clones from SW480
with mutant p53, only a few clones were recovered from
HCT-116 cell line with wild-type p53 although the same
number (106 cells) of HygR cells were plated for both cell
lines to carry out G418 selection (Figure 2a). We con-
cluded that it is the direct eﬀect of retrotransposition in
HCT-116 that results in reduced colony survival.
To test whether the G418R clones generated after
transfection have acquired resistance because the tagged
L1 elements have undergone retrotransposition, we per-
formed a PCR analysis of these clones using primers
ﬂanking the neomycin cassette. The results show that the
retrotransposition marker, the neomycin phosphotrans-
ferase gene, is correctly spliced as evidenced by the detec-
tion of a 468bp DNA fragment (Figure 2b). This was also
shown for HCT-116 and SW480 (Figure 2b,l a n e3 ) .A s
controls, we used genomic DNA from mock-transfected
cells, no DNA, or the DNA plasmid alone. HygR cells did
not show the spliced form in either cell line (lane 2). In
most cases, only the spliced form (468bp) was visualized
on agarose gels, which indicates that only the spliced and
active form of neomycin gene can be stably maintained in
cells. However, the longer unspliced form (1368bp) can
also sometimes be seen as extrachromosomal molecules
in early passage.
To test whether this association between low num-
ber of G418R clones and the p53 status is applicable to
other cell lines, we decided to analyze a panel of cell lines
from diﬀerent tissues having either a wild-type or mutant
p53. This group included two ﬁbrosarcoma cell lines,
HT1080wt (p53 wild type) and its derivative HT1080mut
(p53 mutant); a breast adenocarcinoma cell line, MCF-
7( p53wt); and an NHF (p53wt). The retrotransposition
frequency was scored as described. As before, cell lines188 Abdelali Haoudi et al 2004:4 (2004)
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Figure 2. Human L1 retrotransposition in diﬀerent cancer cell lines. (a) Colony forming ability of HCT-116 and SW480 cell lines.
103 cells either untransfected or transfected with L1 and selected for either hygromycin or G418 resistance were plated in triplicate
until colonies were measurable, then stained and counted. Both cell lines exhibit similar colony forming ability when mock-treated or
selected only for stable transformation with the plasmid (HygR). However, a dramatic diﬀerence in their survival ability was observed
in G418-resistant clones bearing a retrotransposition-competent L1. (b) Conﬁrmation of L1 retrotransposition by PCR in HCT-116
and SW480 cell lines. Lane M: DNA marker λ/HindIII; lane 1: HCT-116 mock-transfected cells; lane 2: HCT-116 HygR cells did not
show the spliced form in either cell line; lane 3: HCT-116 G418R cells showing the correctly spliced form of NEO at 468bp; lane 4:
SW480 mock-transfected cells; lane 5: SW480 HygR cells; lane 6: SW480 G418R cells; lane 7: no DNA; and lane 8: the DNA plasmid
alone with the unspliced form shown at 1361bp.
harboring wild-type p53 were poorly supportive of retro-
transposition (Table 1). In contrast, the cell line with mu-
tant p53 exhibited higher frequencies of retrotransposi-
tion. At this stage, low-frequency retrotransposition can
be explained either by the inability of cells expressing
p53wt to allow high L1 retrotransposition, or the inabil-
ity to detect clones undergoing retrotransposition in cells
because of their immediate loss.
L1inductionofapoptosisinp53(wt)celllines
Since induction of apoptosis is an early event in DNA
damage-mediated p53-dependent response and since p53
wild-type cells exhibit a dramatic decrease in their sur-
vivability after L1 retrotransposition, we examined the
role of apoptosis in the observed diﬀerences in retro-
transposition frequency. We assayed for apoptosis using
a colorimetric assay allowing quantiﬁcation by detection
of DNA fragmentation. A dramatic increase in apopto-
sis was detected in G418R HCT-116 cells, while no in-
duction of apoptosis was detected in G418R SW480 cells
(Figure 3a). A nuclease treatment was used as a positive
control. To conﬁrm that drug selection using G418 is not
associated with the induction of apoptosis, we transfected
these cells with a plasmid containing only the NEO gene
(pBRV1) without the L1 element. No apoptosis was in-
duced in these cells. Thus, these data demonstrate that the
induction of apoptosis is associated with the presence of
retrotransposition-competent L1.
To further test whether the induction of apoptosis is
directly associated with the presence of L1, proteins ex-
tractedfromHCT-116transfectedeitherwiththeL1plas-
mid or with a neomycin plasmid (vector alone) were an-
alyzed by immunoblotting (Figure 3b). The induction of
Bax expression was detected only in G418R cells derived
fromcellstransfectedwith L1 plasmid (lane3). No induc-
tion of Bax expression was observed in mock-transfected
cells (lane 1), HygR cells transfected with L1 (lane 2), or
G418R cells transfected with a plasmid containing only
NEO gene (vector alone) (lane 4).
Suppressionofp53byexpressionofE6ablates
L1-dependentapoptosis
The E6 protein encoded by the oncogenic hu-
man papillomaviruses (HPVs) targets p53 for ubiquitin-
dependent proteolysis [27]. To address the role of a
competent p53 in the induction of apoptosis, we exam-
ined the eﬀects of L1 activity in cells in which p53 is
functionally inactivated by HPV E6 expression. We used
the ability of the HPV E6 gene to inactivate p53 in order
to examine the dependence of L1-mediated apoptosis on
a functional p53 protein. When HCT-116 cells are trans-
formed with L1 they undergo apoptosis and inhibition
of cell growth. When these same cells were transfected to
express a normal E6 gene (L1 + E6), the eﬀect of L1 on
cell growth is reduced and the number of G418 resistant
colonies increased (Figure 4). When a parallel population2004:4 (2004) Human LINE-1 Induces Apoptosis in Cancer Cells 189
Table 1. Analysis of L1 retrotransposition frequency in multiple cell lines. Cells with mutant p53 exhibit high retrotransposition
frequency, while cell lines with wild-type p53 exhibit a lower frequency.
Cell line p53 status Retrotransposition frequency (×106)
HCT-116 wt 68
SW480 mut 1000
DLD-1 mut 760
MCF-7 wt 1.5
HT1080wt wt 6
HT1080mut mut 793
NHF wt < 0.1
3
2.5
2
1.5
1
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Figure 3. Analysis of apoptosis induction in the presence of RC-L1. (a) Apoptosis was highly induced in HCT-116 G418R cells with
a wild-type p53 (G418R L1). No signiﬁcant apoptosis induction was detected in SW480 cells with a mutant p53. Both HCT-116 and
SW480transfectedwiththevectoralone(G418R NEO)didnotshowanyapoptosisinduction.Nucleasetreatmentwasusedaspositive
control.(b)SpeciﬁcinductionofBaxexpressionfollowingL1retrotransposition.HCT-116cellstransfectedwitheithertheL1plasmid
(JM101) or the vector alone (pBRV1). Bax induction was observed only in G418R L1-transfected cells (lane 3). No Bax expression
was observed in mock-transfected cells (lane 1), HygR cells transfected with L1 (Lane 2), or G418R cells transfected with a plasmid
containing a NEO gene alone (lane 4). α-tubulin is shown as loading control.
of HCT-116 cells were transfected to express L1 and a
deleted form of E6 (L1 + ∆E6), the L1 retrotransposition
frequency was reduced and colony formation was similar
to L1 alone. These results are consistent with the notion
that L1-induced apoptosis requires a functional p53.
L1retrotranspositioninisogenicHT1080cells
We have conducted most of our comparative studies
in two colorectal cancer cell lines HCT-116 and SW480.
These cells diﬀer not only by their p53 status, but also
by the status of some DNA repair genes, mainly mis-
match repair genes hMLH1 and hMH6. Therefore, we
cannot rule out the implication of other genes in the ob-
served diﬀerences in these cells ability to undergo apop-
tosis after the addition of retrotransposition-competent
L1elements.Therefore,wefurtherstudiedtheassociation
between L1 retrotransposition and p53 status in the iso-
genic cells HT1080wt, with wild-type p53, and its deriva-
tive HT1080mut, with mutant p53. HT1080 mutant cells
(HT1080TG) have two independent mutations in each
of the p53 alleles and can make p53 [28]. We showed
that G418R clones have indeed undergone the retrotrans-
position for the marked L1 elements, using PCR anal-
ysis. The spliced form of 468bp was detected in both
HT1080wt and HT1080mut after transfection and selec-
tion for G418 resistance (Figure 5a). We analyzed pro-
tein expression levels in HT1080wt and its derivative
HT1080mut by immunoblotting before and after trans-
formation with human L1 (Figure 5b). We found that p53
isoverexpressedaftertransfectionandselectionforG418R
clones harboring retrotransposition-competent L1 ele-
mentsinbothHT1080wtandHT1080mut.Wealsofound
that Bax is overexpressed in HT1080wt in a much more
pronounced manner in comparison with HT1080mut.190 Abdelali Haoudi et al 2004:4 (2004)
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Figure 4. p53 inactivation by human papillomavirus E6 gene. HCT-116 cells transformed with L1 and selected for hygromycin
resistance HygR were either (a) subjected to G418 selection directly (L1) or (b) exposed to either a deleted form of E6, ∆E6 (L1 +
∆E6), or (c) a complete form of E6 (L1 + E6). A histogram showing the eﬀects of L1 retrotransposition on the number of clones in
the presence and absence of E6 is shown in (d).
We quantiﬁed the diﬀerences in Bax expression between
HT1080wt and HT1080mut by densitometric analysis
(Figure 5c). While we found that Bax expression was in-
duced relatively about 8 times in HT1080wt, the dif-
ference was less than double in HT1080mut cells. In
addition, we observed a decrease in Bcl2 expression
level following L1 retrotransposition in HT1080wt cells
(Figure 5d) and to a slightly lower extent in HT1080mut
cells (Figure 5e). This is in agreement with p53 being in-
volved in the induction of apoptosis following L1 retro-
transposition, and in agreement with our ﬁnding in other
cell lines where we have observed a more pronounced in-
duction of apoptosis in cells with wild-type p53.
DISCUSSION
Our understanding of the biology of L1 element, its
retrotransposition mechanism, and its ability to retro-
transpose in human cultured cells has increased over
the last several years [29, 30]. However, the cellular
consequences of the presence of L1 sequences and the
support of L1 retrotransposition on the stability of the
genomearestillpoorlyunderstood.Indeed,itisbecoming
increasingly apparent that human L1 retrotransposition
impactsthestabilityofthehumangenomeandevidenceis
mounting that human L1 is more than just an insertional
mutagen [31, 32, 33]. Interestingly, Morrish et al reported
that L1 is capable of mediating DNA repair. Speciﬁcally,
theauthorsshowedthattheL1elementiscapableofretro-
transposition using a pathway independent of endonu-
clease but dependent on reverse transcriptase, suggesting
that L1 can integrate into preexisting DNA lesions re-
sulting in retrotransposition-mediated DNA repair [33].
Conversely, it has also been shown that human L1 retro-
transposition induces genetic instability in vivo through
numerous L1 element inversions, extra nucleotide in-
sertions, exon deletions, chromosomal inversion, and 5 
transduction[30].Thus,L1hasbeenassociatedwithboth
stabilizing and destabilizing molecular activities. The vast
majority of these studies have not addressed the conse-
quences of L1 transposition on genetic instability and cell
growth.2004:4 (2004) Human LINE-1 Induces Apoptosis in Cancer Cells 191
HT1080wt HT1080mut
468bp
(a)
HT1080wt HT1080mut
12 12
p53
Bax
α-tubulin
(b)
1400
1200
1000
800
600
400
200
0
H
T
1
0
8
0
w
t
H
T
1
0
8
0
w
t
-
G
4
1
8
H
T
1
0
8
0
m
u
t
H
T
1
0
8
0
m
u
t
-
G
4
1
8
(c)
12
Bcl2
α-tubulin
(d)
12
Bcl2
α-tubulin
(e)
Figure 5. L1 retrotransposition in isogenic HT1080 cells. (a) Conﬁrmation of L1 retrotransposition in HT1080wt and HT1080mut
cells:a468 bpDNAfragmentwasgeneratedbyPCRinHT1080wtandHT1080mutG418R clonesdemonstratingacorrectsplicingof
theNEOmarkergene.(b)Westernblotanalysis:wholecellextractsfromHT1080wtandHT1080mutcellsshowinganincreaseofBax
expression following transfection with human L1 (1) and selection for G418R clones (2) harboring L1-retrotransposition elements
predominantly in HT1080wt. (c) Densitometric analysis of Bax expression levels in HT1080wt and HT1080mut before and after
generation of G418R clones. More pronounced increase of Bax expression in HT1080wt in comparison with HT1080mut. Shown are
relative arbitrary numbers. (d) Western blot analysis of HT1080wt cells: Bcl2 expression before transfection (1) and after selection of
G418R clones following L1 retrotransposition (2). (e) Western blot analysis of HT1080mut cells: Bcl2 expression before transfection
(1) and after selection of G418R (2). α-tubulin is shown as loading control.
In this study we analyzed the impact of L1 retro-
transposition on human cancer cell growth and showed
that L1 retrotransposition can elicit a DNA damage re-
sponse leading to apoptosis in p53 competent cells. Thus,
the overriding cellular consequences of L1 retrotranspo-
sition would appear to derive from genome destabilizing
activities. We suggest two possible mechanisms through
which L1 elements might induce apoptosis. First, since192 Abdelali Haoudi et al 2004:4 (2004)
L1 creates DNA strand breaks using its own endonuclease
to create nicks in the insertion sites, these events might
be recognized by the cell as unrepaired DNA damage.
This would be especially true if the transposition were
massively induced thus triggering pathways for apopto-
sis. Despite the fact that the proteins encoded by L1 ele-
ments work preferentially in cis, members of the Alu class
of retroelements are believed to misappropriate L1 pro-
teins in order to proliferate [6, 34, 35]. Therefore, the
introduction of exogenous retrotransposition-competent
L1 elements into cells by transfection may activate not
only endogenous L1 but probably also Alu sequences by
providing in trans encoded proteins such as reverse tran-
scriptase, thus contributing to a burst of transposition.
Pertinent to this discussion it was recently reported that
L1 reverse transcriptase can transactivate other endoge-
nousL1sequencesandevenotherL1-unrelatedsequences
[36, 37, 38]. Thus, the delivery of retrotransposition-
competent L1 elements into cancer cells can transactivate
other endogenous repressed or “dormant” L1 and Alu se-
quences leading to a release of “jumping” L1s and Alus,
that are ultimately sensed by the DNA repair machinery
as a stress signal. A second possible mechanism is that a
class of ribonucleoprotein particles (RNPs), consisting of
transposition complexes that contain L1 RNA and the L1-
encoded proteins, might separately elicit apoptosis. The
heteronuclear ribonucleoproteins (hnRNPs) C1 and C2
are targets of destruction within the cell that has been in-
duced to undergo apoptosis by a variety of stimuli [39].
L1-RNPsmightbeinducersinadditiontotargetsofapop-
tosis. While we have yet to uncover the detailed mech-
anism through which human L1 is capable of inducing
apoptosis in cancer cells with wild-type p53, our ﬁndings
demonstrate an interplay between L1 retrotransposition
and p53-mediated-induction of apoptosis in cells harbor-
ing retrotransposition-competent L1s.
Our ﬁnding supports a hypothesis in which the Bax
gene plays a role in the L1-induced apoptosis in p53 wild-
type cells. In addition to Bax gene, there is still a growing
list of genes stimulated by p53 which are associated with
apoptosis induction, such as Fas, CD95, DR5/killer, p85,
IGF-BP3, PAG608, and so forth. It should be noted that
several of these proapoptotic genes, as is also the case with
Bax, appear to be cell-type-speciﬁc and signal-dependent.
In our study, the induction of Bax expression and repres-
sion of Bcl2 expression following L1 retrotransposition in
both HCT-116 and HT1080 cells indicate that induction
of apoptosis by L1 involves activation via pathway regu-
lated by the Bax gene.
The apoptotic gene Fas which is a cell surface “death
receptor” mediates apoptosis upon engagement by its lig-
and, FasL. Many studies of transformed colon cell lines,
such as these used in this study as well as freshly isolated
tumor cells of diverse origin have revealed that the major-
ity of cancer cells are resistant to Fas-mediated apoptosis
[40, 41, 42, 43]. For these reasons we did not analyze Fas
and FasL-mediated apoptosis in the colon cancer cell lines
after L1 transposition.
In any case, the induction of retrotransposition would
facilitate the apoptotic response in p53+/+ cells and the
molecular events involved in sensing L1-induced stress
need to be conﬁrmed in order to shed some light on an
important mechanism of inducing apoptosis in p53 com-
petent cancer cells.
HumanL1asapotentialnovelcancertherapeutic
strategybasedontheinduction
ofapoptosis:perspectives
Both chemotherapeutic agents and irradiation can in-
duce tumor cell death primarily by causing DNA dam-
age. However, it has been very diﬃcult to limit damage to
normal tissue to an acceptable level using these therapies.
Although a number of methods to induce target cells to
undergo apoptosis exist and are being evaluated, any ap-
proach which can be selectively targeted to the cancer cell
oﬀers an advantage to existing methods. The activation of
L1retrotranspositioninducesgenomicinstability,thereby
triggering a DNA damage response, which results in the
delay of cell cycle progression and/or induction of apop-
tosis. Using an endogenous component of the genome for
a preferential induction of apoptosis within tumor cells
could provide a novel mode of attack for cancer therapeu-
tics.Theemploymentofsophisticatedcell-speciﬁcvectors
asgenetherapytoolswillenabletargetingofL1onlytotu-
mor cells.
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